Table 1 Baseline characteristics of the patients

Sex

Male

849

57.0 (%)

210

67.5 (%)

P = 0.0006

Female

640

43.0 (%)

101

32.5 (%)

Age (y.o.)

n

1,489

311

P < 0.0001

Mean S.D

70

15.5

73.6

13.5

Median

73

76

Body weight (kg)

n

1,472

303

P = 0.5389

Mean S.D

55.4

13

55.9

14.6

Median

54.4

55

SOFA score

n

1,298

264

P < 0.0001

Mean S.D

8.9

3.7

11.7

3.9

Median

9

12

JAAM DIC score

n

1,489

311

P = 0.7520

Mean S.D

5.6

1.4

5.6

1.3

Median

5

5

Baseline antithrombin activity

n

1,489

311

P < 0.0001

Mean S.D

48.5

12.2

43.7

13.1

Median

50

43.4

Source of infection

Pneumonia

269

18.1 (%)

117

37.6 (%)

P < 0.0001

Digestive tract

377

25.3 (%)

65

20.9 (%)

P = 0.1109

Pyelonephritis

215

14.4 (%)

20

6.4 (%)

P < 0.0001

Biliary tract

138

9.3 (%)

20

6.4 (%)

P = 0.1227

Skin/soft tissue

98

6.6 (%)

33

10.6 (%)

P = 0.0162

Urinary tract

35

2.4 (%)

3

1.0 (%)

P = 0.1891

Intravenous catheter

54

3.6 (%)

7

2.3 (%)

P = 0.2999

Others

92

6.2 (%)

15

4.8 (%)

P = 0.4291

unknown

187

12.6 (%)

72

23.2 (%)

P < 0.0001

Co-administration

Heparin

236

15.8 (%)

56

18.0 (%)

P = 0.3527

Protease inhibitor

306

20.6 (%)

61

19.6 (%)

P = 0.7572

Thrombomodulin

871

58.5 (%)

189

60.8 (%)

P = 0.4860

Daily dose of antithrombin concentrate (IU)

n

1,489

311

P = 0.5948

Mean S.D

1571.6

450.5

1586.4

424.9

Median

1500

1500

Duration of antithrombin concentrate (day)

n

1,489

311

P = 0.0143

Mean S.D

3.2

1.9

3.5

2.2

Median

3

3

Total dose of antithrombin concentrate (IU)

n

1,489

311

P < 0.0001

Mean S.D

4736.8

1905.2

5308.3

2311.1

Median

4500

4500